Lisata Therapeutics (LSTA) Competitors $2.60 -0.20 (-7.14%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$2.90 +0.30 (+11.54%) As of 08/8/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LSTA vs. SRZN, IVVD, QNCX, ADAG, XBIT, ORMP, VTGN, MGX, VXRT, and BYSIShould you be buying Lisata Therapeutics stock or one of its competitors? The main competitors of Lisata Therapeutics include Surrozen (SRZN), Invivyd (IVVD), Quince Therapeutics (QNCX), Adagene (ADAG), XBiotech (XBIT), Oramed Pharmaceuticals (ORMP), VistaGen Therapeutics (VTGN), Metagenomi (MGX), Vaxart (VXRT), and BeyondSpring (BYSI). These companies are all part of the "pharmaceutical products" industry. Lisata Therapeutics vs. Its Competitors Surrozen Invivyd Quince Therapeutics Adagene XBiotech Oramed Pharmaceuticals VistaGen Therapeutics Metagenomi Vaxart BeyondSpring Surrozen (NASDAQ:SRZN) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk. Does the media prefer SRZN or LSTA? In the previous week, Surrozen had 1 more articles in the media than Lisata Therapeutics. MarketBeat recorded 8 mentions for Surrozen and 7 mentions for Lisata Therapeutics. Surrozen's average media sentiment score of 0.89 beat Lisata Therapeutics' score of 0.48 indicating that Surrozen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Surrozen 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lisata Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Do institutionals and insiders believe in SRZN or LSTA? 66.6% of Surrozen shares are owned by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are owned by institutional investors. 43.5% of Surrozen shares are owned by company insiders. Comparatively, 9.1% of Lisata Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has better valuation and earnings, SRZN or LSTA? Lisata Therapeutics has lower revenue, but higher earnings than Surrozen. Lisata Therapeutics is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSurrozen$10.65M7.68-$63.56M-$24.96-0.38Lisata Therapeutics$1M22.78-$19.99M-$2.30-1.13 Is SRZN or LSTA more profitable? Lisata Therapeutics has a net margin of 0.00% compared to Surrozen's net margin of -274.42%. Lisata Therapeutics' return on equity of -69.68% beat Surrozen's return on equity.Company Net Margins Return on Equity Return on Assets Surrozen-274.42% -842.90% -71.78% Lisata Therapeutics N/A -69.68%-59.44% Which has more volatility & risk, SRZN or LSTA? Surrozen has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500. Comparatively, Lisata Therapeutics has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500. Do analysts recommend SRZN or LSTA? Surrozen presently has a consensus target price of $38.50, indicating a potential upside of 302.72%. Lisata Therapeutics has a consensus target price of $23.50, indicating a potential upside of 803.85%. Given Lisata Therapeutics' higher probable upside, analysts plainly believe Lisata Therapeutics is more favorable than Surrozen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Surrozen 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Lisata Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryLisata Therapeutics beats Surrozen on 8 of the 14 factors compared between the two stocks. Get Lisata Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LSTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LSTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LSTA vs. The Competition Export to ExcelMetricLisata TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$22.76M$2.99B$5.50B$9.72BDividend YieldN/A2.28%4.59%4.12%P/E Ratio-1.1717.1130.0524.70Price / Sales22.78330.47456.53100.55Price / CashN/A40.7324.8428.01Price / Book0.748.888.525.76Net Income-$19.99M-$54.75M$3.27B$267.05M7 Day Performance4.63%0.01%6.13%5.08%1 Month Performance-5.11%0.64%0.07%0.61%1 Year Performance-10.96%8.71%36.43%22.83% Lisata Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LSTALisata Therapeutics2.8625 of 5 stars$2.60-7.1%$23.50+803.8%-11.0%$22.76M$1M-1.1730News CoverageEarnings ReportGap DownSRZNSurrozen2.7598 of 5 stars$10.66-2.6%$38.50+261.2%+33.7%$91.25M$10.65M-0.4380News CoverageEarnings ReportUpcoming EarningsIVVDInvivyd3.1443 of 5 stars$0.76+4.0%$5.85+672.8%-22.5%$90.69M$36.69M-0.63100News CoverageUpcoming EarningsQNCXQuince Therapeutics3.0118 of 5 stars$1.68+3.1%$8.29+393.2%+139.1%$90.09MN/A-1.2160Upcoming EarningsAnalyst ForecastShort Interest ↑ADAGAdagene2.9303 of 5 stars$1.89-1.6%$8.00+324.4%-10.3%$88.80M$100K0.00260News CoverageAnalyst ForecastAnalyst RevisionXBITXBiotech0.8271 of 5 stars$2.85-0.1%N/A-55.7%$86.78M$4.01M-2.21100Positive NewsUpcoming EarningsORMPOramed Pharmaceuticals0.3058 of 5 stars$2.12+1.4%N/A-10.7%$86.60M$1.34M-4.8210News CoveragePositive NewsUpcoming EarningsVTGNVistaGen Therapeutics1.2973 of 5 stars$2.86-1.9%N/A-12.9%$85.25M$490K-1.7240News CoverageEarnings ReportUpcoming EarningsGap UpMGXMetagenomi2.5906 of 5 stars$2.28-0.9%$13.00+470.2%-33.3%$85.23M$52.29M-1.08236News CoverageUpcoming EarningsVXRTVaxart2.7071 of 5 stars$0.370.0%$3.00+711.2%-34.5%$84.65M$47.40M-1.37120News CoverageUpcoming EarningsBYSIBeyondSpringN/A$2.10-2.8%N/A+3.1%$84.63M$1.75M0.0080Upcoming EarningsGap Down Related Companies and Tools Related Companies Surrozen Competitors Invivyd Competitors Quince Therapeutics Competitors Adagene Competitors XBiotech Competitors Oramed Pharmaceuticals Competitors VistaGen Therapeutics Competitors Metagenomi Competitors Vaxart Competitors BeyondSpring Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LSTA) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersI trusted Trump and got screwedPorter Stansberry says he got one thing wrong—and now millions of Americans could pay the price. After warning...Porter & Company | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lisata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lisata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LSTA Stock Alerts